NCT00740805 2026-03-18
Veliparib, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Non-Hodgkin Lymphoma
National Cancer Institute (NCI)
Phase 1 Active not recruiting
Clinical Trials
6 trialsNCT01351909 2026-03-18
Cyclophosphamide and Veliparib in Treating Patients With Locally Advanced or Metastatic Breast Cancer
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT01434316 2026-03-18
Veliparib and Dinaciclib in Treating Patients With Advanced Solid Tumors
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT01251874 2025-11-21
Veliparib and Carboplatin in Treating Patients With HER2-Negative Metastatic Breast Cancer
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT01139970 2025-11-20
Veliparib and Temozolomide in Treating Patients With Acute Leukemia
National Cancer Institute (NCI)
Phase 1 Completed
NCT00576654 2025-04-15
Veliparib and Irinotecan Hydrochloride in Treating Patients With Cancer That Is Metastatic or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 1 Completed